Sign In
Buy CMPS
$13.19
-0.455 (-3.34%)
At Close: Jul 13, 2026
Compass Pathways Eyes 2027 Launch as Psilocybin Depression Data Holds Up
03:03am, Friday, 10'th Jul 2026
Compass Pathways NASDAQ: CMPS said new 26-week data from its Phase 3 COMP006 trial further support the durability and safety profile of COMP360, its investigational psilocybin therapy for treatment-re
Compass Pathways: 'Strong Buy' COMP360 Trial Wins And Q4 NDA Full Submission
01:23pm, Wednesday, 08'th Jul 2026
Compass Pathways: 'Strong Buy' COMP360 Trial Wins And Q4 NDA Full Submission
COMPASS Pathways plc (CMPS) Discusses Six-Month Data from Second Phase 3 Trial Confirming Rapid and Durable Profile in Depression Transcript
Compass Pathways Highlights Long-Term Data from Resistant Depression, Backs 2027 Launch Timeline
12:24pm, Tuesday, 07'th Jul 2026
Compass Pathways plc (NASDAQ:CMPS) on Wednesday reported 26-week results from Part B of its Phase 3 COMP006 trial, reinforcing the rapid and durable efficacy of COMP360, its synthetic psilocybin thera
Compass Pathways Announces Six-Month Data from Second Phase 3 Trial Confirming Rapid and Durable Profile
06:30am, Tuesday, 07'th Jul 2026
LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced tod
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
06:30am, Thursday, 02'nd Jul 2026
LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental heal
A Breakthrough-Designated Depression Drug Is 86% Through Its Phase 3, With Topline Data Due This Year
09:30am, Friday, 26'th Jun 2026
Issued on behalf of Helus Pharma™ Helus Pharma™ (NASDAQ: HELP) (Cboe CA: HELP), the commercial operating name of Cybin Inc., says its APPROACH Phase 3 trial of HLP003 for adjunctive treatment of m
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
06:30am, Friday, 05'th Jun 2026
LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental heal
Compass Pathways Elects Kathleen Tregoning to Board of Directors
06:30am, Thursday, 28'th May 2026
LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental heal
Compass Pathways: A Trip Worth Taking Before The FDA Verdict
08:39am, Wednesday, 27'th May 2026
COMPASS Pathways (CMPS) is positioned to pioneer COMP360, the first psychedelic drug for treatment-resistant depression (TRD), with expected FDA approval later this year. COMP360 demonstrated primary
Compass Pathways Eyes Q4 FDA Filing for Psilocybin Depression Drug After Phase 3 Wins
02:03am, Thursday, 21'st May 2026
Compass Pathways NASDAQ: CMPS executives said the company remains on track to target a fourth-quarter New Drug Application filing for COMP360, its synthetic psilocybin treatment candidate for treatmen
Compass Pathways: Imminent Commercialization Should Provide Further Upside
08:36pm, Thursday, 14'th May 2026
Compass Pathways is nearing an inflection point, with solid Phase III data and government support pointing towards a likely FDA approval. CMPS is positioned to address the large, underserved treatment
Compass Pathways to Participate in RBC Capital Markets Global Healthcare Conference on May 19-20, 2026
07:00am, Thursday, 14'th May 2026
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced
Compass Pathways to Participate in RBC Capital Markets Global Healthcare Conference on May 19-20, 2026
06:30am, Thursday, 14'th May 2026
LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental heal
COMPASS Pathways plc (CMPS) Q1 2026 Earnings Call Transcript
04:00pm, Wednesday, 13'th May 2026
COMPASS Pathways plc (CMPS) Q1 2026 Earnings Call Transcript
